海外の治験の状況「1」での検索結果
11979件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Not Recruiting
- A Single Center, Double Blind, Randomized Crossover Study Evaluating the Bioequivalence of VIAject®7 compared to VIAject™25 and Comparing the Pharmacokinetic and Pharmacodynamic Properties of VIAject®7 to Insulin Lispro in Subjects with Type 1 Diabetes Mellitus
- Type 1 Diabetes Mellitus br>MedDRA version: 9.1 Level: LLT Classification code 10045238 Term: Type I diabetes mellitus without mention of complication
- Germany
- 2009-04-21
Not Recruiting
- Randomised, single-blind, placebo controlled, four-period four-treatment cross-over design, proof of concept study to compare the pharmacodynamic, safety and pharmacokinetics of one single administration of SKP-1052 versus immediate-release terbutaline and placebo tablets in stable Type 1 Diabetes Mellitus Patients
- Type 1 Diabetes Mellitus br>MedDRA version: 12.1 Level: LLT Classification code 10012601 Term: Diabetes mellitus MedDRA version: 12.1 Level: LLT Classification code 10012608 Term: Diabetes mellitus insulin-dependent MedDRA version: 12.1 Level: LLT Classification code 10012610 Term: Diabetes mellitus loss of control
- Germany
- 2010-12-08
Not Recruiting
- Phase II randomized trial of the Polo-like kinase 1 inhibitor BI 6727 monotherapy versus investigator’s choice chemotherapy in ovarian cancer patients resistant or refractory to platinum-based cytotoxic therapy - BI 6727 randomised phase II trial in ovarian cancer
- Recurrent ovarian cancer resistant or refractory to platinum compounds
- Belgium, France, Slovakia, Spain, Sweden
- 2010-02-01
Authorised
- Effect of insulin glulisine compared to insulin aspart and insulin lispro when administered by Continuous Subcutaneous Insulin Infusion (CSII) on specific pump parameters in patient with Type 1 Diabetes Mellitus - Pump Study
- Type I Diabetes Mellitus MedDRA version: 9.1 Level: LLT Classification code 10045228 Term: Type I diabetes mellitus
- Austria, France, Hungary, Italy, Netherlands, Spain, Sweden, United Kingdom
- 2007-10-04
Authorised
- A Phase 2/3, Randomized, Double-Blind, Multicenter, Multinational, 4-Arm, Controlled, Dose-Ranging Study to Evaluate Efficacy and Safety of Teplizumab (MGA031), a Humanized, FcR Non-Binding, Anti-CD3 Monoclonal Antibody, in Children and Adults with Recent-Onset Type 1 Diabetes Mellitus - Protégé
- Recent-onset type I diabetes mellitus (T1DM) MedDRA version: 9.0 Level: LLT Classification code 10045228
- Estonia, Germany, Latvia, Netherlands, Spain, Sweden, United Kingdom
- 2006-10-19
Authorised
- A study of AZD4547 in patients with tumours having high number of copies of the FGFR1 or FGFR2 gene.
- Advanced Breast Cancer Advanced Lung Cancer Advanced Upper gastrointestinal cancer
- United Kingdom
- 2011-11-22
Authorised
- Randomized, open label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with hormone therapy driven by circulating DNA ESR1 mutation monitoring in estrogen receptor-positive, HER2-negative metastatic breast cancer patients PADA-1 (PAlbociclib and circulating tumor DNA for ESR1 mutation detection) - PADA-1
- HER-2 negative metastatic breast cancer;Therapeutic area: Diseases [C] - Cancer [C04]
- France
- 2017-02-02
Not Recruiting
- A Phase III, Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group Study of the Safety and Efficacy of the Intravenous and Oral Formulations of the Neurokinin-1 Receptor Antagonist, Casopitant (GW679769) in Combination with Ondansetron and Dexamethasone for the Prevention of Nausea and Vomiting Induced By Moderately Emetogenic Chemotherapy
- Chemotherapy induced nausea and vomiting (CINV) due to Moderately Emetogenic Chemotherapy (MEC) MedDRA version: 8.1 Level: LLT Classification code 10008448 Term: Chemotherapy induced emesis prophylaxis
- Czech Republic, Denmark, Estonia, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Spain, United Kingdom
- 2006-05-08
Authorised
- A Phase III, Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group Study of the Safety and Efficacy of the Intravenous and Oral Formulations of the Neurokinin-1 Receptor Antagonist, Casopitant (GW679769) in Combination with Ondansetron and Dexamethasone for the Prevention of Nausea and Vomiting Induced By Moderately Emetogenic Chemotherapy
- Chemotherapy induced nausea and vomiting (CINV) due to Moderately Emetogenic Chemotherapy (MEC)
- Czech Republic, Denmark, Estonia, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Spain, United Kingdom
- 2006-04-28
Not Recruiting
- A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose-ranging, Parallel Group Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of the Oral Neurokinin-1 Receptor Antagonist, GW679769, When Administered with Intravenous Ondansetron Hydrochloride for the Prevention of Post-operative Nausea and Vomiting (PONV) and Post-discharge Nausea and Vomiting (PDNV) in Female Subjects
- Post Operative Nausea and Vomiting (PONV) Post Discharge Nausea and Vomiting (PDNV)
- Germany, Hungary, Spain
- 2005-03-25
Authorised
- METFORMIN VS PLACEBO IN NEWLY DIAGNOSED TYPE 1 DIABETES MELLITUS: A RANDOMIZED CLINICAL TRIAL - ND
- NEWLY DIAGNOSED TYPE 1 DIABETES MELLITUS br>MedDRA version: 9.1 Level: LLT Classification code 10045228 Term: Type I diabetes mellitus
- Italy
- 2008-09-18
Authorised
- A MULTICENTER OPEN LABEL PHASE II STUDY OF THE EFFICACY AND SAFETY OF AMG 479, A FULLY HUMAN MONOCLONAL ANTIBODY AGAINST INSULIN-LIKE GROWTH FACTOR TYPE 1 RECEPTOR (IGF-1R) AS SECOND LINE THERAPY IN PATIENTS WITH RECURRENT PLATINUMSENSITIVE OVARIAN CANCER
- Recurrent Platinum-sensitive ovarian cancer MedDRA version: 9.1 Level: LLT Classification code 10033128 Term: Ovarian cancer
- France, Germany, Ireland, Spain
- 2008-08-22
Not Recruiting
- A Multicentre, Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel Group, Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Oral (25 mg) and Intravenous (3 mg and 18 mg) Formulations of the Neurokinin-1 Receptor Antagonist, GW597599, When Administered with Intravenous Ondansetron Hydrochloride for the Prevention of Post-operative Nausea and Vomiting and Post-discharge Nausea and Vomiting in Female Subjects with Known Risk Factors for PONV - N/A
- Post Operative Nausea and Vomiting (PONV) Post Discharge Nausea and Vomiting (PDNV)
- Czech Republic, Finland
- 2004-11-11
Recruiting
- Phase II Trial of Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2)
- Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma
- France
- 2018-10-09
Not recruiting
- Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE)
- Small Cell Lung Cancer
- Australia, Belarus, Belgium, Brazil, Bulgaria, Canada, China, Croatia, Czechia, Denmark, Finland, France, Germany, Greece, Hungary, Italy, Japan, Korea, Republic of, Latvia, Mexico, Netherlands, Poland, Portugal, Romania, Russian Federation, Serbia, Singapore, Spain, Sweden, Taiwan, Turkey, Ukraine, United Kingdom, United States
- 2017-02-20
Not recruiting
- Long-term Retinal Changes After Topical Citicoline Administration in Patients With Mild Signs of Diabetic Retinopathy in Type 1 Diabetes Mellitus.
- Diabetic Retinopathy
- Italy
- 2019-06-06
Not recruiting
- Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial)
- Solid Tumor
- Australia, Austria, Brazil, Bulgaria, Croatia, Czechia, Denmark, Finland, France, Greece, Korea, Republic of, Netherlands, Norway, Philippines, Poland, Romania, Russian Federation, Singapore, Spain, Taiwan, Ukraine, United Kingdom, United States
- 2019-02-04
Recruiting
- First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma
- Malignant Progressive Pheochromocytoma and Paraganglioma (PPGL);Malignant Progressive Pheochromocytoma and Paraganglioma (PPGL);Malignant Progressive Pheochromocytoma and Paraganglioma (PPGL);Malignant Progressive Pheochromocytoma and Paraganglioma (PPGL)
- France, Germany, Italy, Netherlands
- 2011-06-09
Not recruiting
- Comparison of Diagnostic Performances of 68Ga-DOTATATE PET-CT and 18F-FDOPA PET-CT in Paragangliomas and Pheochromocytomas Evaluation
- Paragangliomas;Pheochromocytomas
- France
- 2014-06-04
Not recruiting
- Impact of CES1 Genotype on Metabolism of Methylphenidate
- Carboxylesterase 1 (CES1) Genotype;CES1 Activity
- Denmark
- 2014-05-22